AZP 2006

Drug Profile

AZP 2006

Alternative Names: AZP2006

Latest Information Update: 03 Nov 2015

Price : $50

At a glance

  • Originator AlzProtect; INSERM; University of Lille 2
  • Developer AlzProtect
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Dementia; Progressive supranuclear palsy

Most Recent Events

  • 26 Mar 2015 The ANSM approves a clinical trial application for AZP 2006 in France
  • 26 Mar 2015 Alzprotect completes a phase I trial in healthy volunteers in France
  • 26 Feb 2015 AZP 2006 receives Orphan Drug status for Progressive supranuclear palsy in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top